3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Completed
6
Recruiting
3
Active not recruiting
2
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
24
Neoplasm Metastasis
2
Urogenital Neoplasms
1
Stage IV Prostate Adenocarcinoma AJCC v7
1
Radiation Injuries
1
Prostatic Diseases
1
Prostate Adenocarcinoma
1
PSA Level Greater Than 0.03
1
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
1
Neoplasms
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castrate-sensitive Prostate Cancer
1
Hormone Sensitive Prostate Cancer
1
Genital Neoplasms, Male
1
Interventions
pembrolizumab
34
Specimen Handling
18
Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Carboplatin
14
Biopsy
14
Nivolumab
13
Ipilimumab
12
Gemcitabine
10
Irinotecan
9
Radiosurgery
8
atezolizumab
7
abemaciclib
7
Radiation
7
Pemetrexed
7
Cisplatin
7
Capecitabine
7
130-nm albumin-bound paclitaxel
7
trastuzumab deruxtecan
6
olaparib
6
durvalumab
6
avelumab
6
Docetaxel
6
osimertinib
5
adagrasib
5
Trastuzumab
5
Fulvestrant
5
Cetuximab
5
Albumin-Bound Paclitaxel
5
palbociclib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasm Metastasis
×
Androgen Antagonists
×
Clear all
NCT02454543
2026-01-12
g-RAMPP
Martini-Klinik am UKE GmbH
Phase NA
Active not recruiting
452 enrolled
NCT03569241
2024-12-09
STORM
University Hospital, Ghent
Phase 2
Active not recruiting
196 enrolled